natgillin/translations-raw huggingface dataset:
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
Pokazala je, da se je v primerjavi z dobrimi metabolizatorji izpostavljenost aktivnemu presnovku pri srednjih metabolizatorjih za 28 % zmanjšala, pri slabih metabolizatorjih se je zmanjšala za 72 %, zavrtje agregacije trombocitov (5 µM ADP) pa se je zmanjšalo tako, da je bila razlika IPA v primerjavi z dobrimi metabolizatorji pri prvih 5,9 % in pri drugih 21,4 %.
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. 
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade trombocitne aktivacije, ki jo je povzročil sproščeni ADP.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Po večkratnem odmerjanju 75 mg klopidogrela na dan, je bilo pri osebah s hudo ledvično boleznijo (kreatininski očistek 5 do 15 ml/min) zaviranje z ADP sprožene agregacije trombocitov manjše (za 25 %) od zaviranja pri zdravih osebah.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36 % odds reduction in favor of clopidogrel (95% CI: 24, 47%; p < 0.001), mainly related to a reduction in occluded infarct-related arteries. 
Primarni opazovani dogodek je bil opažen pri 15 % bolnikov v skupini, zdravljeni s klopidogrelom, in 21¸7 % bolnikov v placebo skupini, kar predstavlja absolutno zmanjšanje za 6,7 % in 36-odstotno zmanjšanje verjetnosti v korist klopidogrela (95-odstotni IZ: 24 do 47 %; p < 0,001), v glavnem zaradi zmanjšanja zaradi infarkta zamašenih arterij.
Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn. 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): Driska, bolečina v trebuhu, slaba prebava ali zgaga.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
O kancerogenem učinku klopidogrela v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat večjo izpostavljenost kot pri človeku ob jemanju kliničnega odmerka 75 mg na dan), ki so ga mišim dajali 78 tednov, podganam pa 104 tedne, ni bilo dokazov.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies. 
Naključno so bili razporejeni v skupino, ki je jemala klopidogrel (začetni odmerek 300 mg, nato 75 mg na dan, n = 6.259) in v skupino, ki je jemala placebo (n = 6.303), oboje v kombinaciji z ASA (75-325 mg enkrat na dan) in drugimi standardnimi terapijami.
than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Če ste vzeli večji odmerek zdravila Clopidogrel Krka d.d., kot bi smeli Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
Koristnosti zdravljenja s kombinacijo klopidrogela in ASA, če bi trajalo dalj kot štiri tedne, v tem okviru niso proučevali (glejte poglavje 5.1).
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
- odraslih bolnikih z akutnim koronarnim sindromom: - akutni koronarni sindrom brez elevacije ST-spojnice (nestabilna angina ali miokardni infarkt brez Q-zobca), vključno z bolniki, ki jim je bila po perkutani koronarni intervenciji vstavljena žilna opornica, v kombinaciji z acetilsalicilno kislino (ASA-acetylsalicylic acid); - akutni miokardni infarkt z elevacijo ST-spojnice v kombinaciji z ASA pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
If you are breast-feeding or planning to breast-feed, talk to your doctor before taking this medicine. 
Če dojite ali nameravate dojiti, se pred jemanjem tega zdravila posvetujte z zdravnikom.
The number of patients who reached the primary endpoint (time to first occurrence of stroke, MI, non-CNS systemic embolism or vascular death) was 832 (22.1%) in the group treated with clopidogrel + ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes. 
Primarni opazovani dogodek (čas do prvega pojava možganske kapi, MI, sistemske embolije (ne v osrednjem živčevju) ali žilne smrti) je doseglo v skupini s klopidogrelom + ASA 832 (22,1 %) bolnikov in v skupini s placebom + ASA 924 (24,4 %) bolnikov (relativno zmanjšanje tveganja 11,1 %, 95 % IZ: od 2,4 % do 19,1 %, p = 0,013), predvsem kot posledica velikega zmanjšanja incidence možganskih kapi.
- a recent serious injury - a recent surgery (including dental) - a planned surgery (including dental) in the next seven days - if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days - if you have kidney or liver disease - if you have had an allergy or reaction to any medicine used to treat your disease. 
: - če pri vas obstaja tveganje za krvavitev, kot je: - zdravstveno stanje s tveganjem za notranjo krvavitev (rana na želodcu), - krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa), - nedavna huda poškodba, - nedavni kirurški poseg (tudi na zobeh), - načrtovan kirurški poseg (tudi na zobeh) v naslednjih sedmih dneh; - če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh, - če imate ledvične ali jetrne bolezni, - če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali.
Rash, pruritus, skin bleeding (purpura) 
Bolezni kože in podkožja modrice izpuščaj, srbenje, kožne krvavitve (purpura)
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Dobivali so klopidogrel (udarni odmerek 300 mg, nato po 75 mg na dan, n = 1.752) ali placebo (n = 1.739), oboje v kombinaciji z ASA (150-325 mg kot udarni odmerek, nato 75-162 mg na dan), s fibrinolitičnim sredstvom in po potrebi heparinom.
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group. 
Bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI, možganska kap ali neodzivna ishemija) je bilo v skupini, zdravljeni s klopidogrelom, 1.035 (16,5 %), v placebo skupini pa 1.187 (18,8 %), kar pomeni 14-odstotno zmanjšanje RT (95-odstotni IZ: 6-21 %, p = 0,0005) v skupini, ki se je zdravila s klopidogrelom.
Method of administration For oral use. 
Za peroralno uporabo.
If you forget to take Clopidogrel Krka d.d. 
Če ste pozabili vzeti zdravilo Clopidogrel Krka d.d.
No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultrarapid, extensive and intermediate metabolisers. 
Med ultrahitrimi, dobrimi in srednjimi metabolizatorji niso ugotovili bistvenih razlik v izpostavljenosti aktivnemu presnovku in povprečnem zavrtju agregacije trombocitov (IPA).
and acetylsalicylic acid for this condition. 
in acetilsalicilne kisline.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. 
Mehanizem delovanja Klopidogrel je predzdravilo in eden od njegovih presnovkov zavira agregacijo trombocitov.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension 
Žilne bolezni hematom resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups. 
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + ASA, 0,7 %
Do not take Clopidogrel Krka d.d. 
Ne jemljite zdravila Clopidogrel Krka d.d.
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A4.The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation. 
Aktivni presnovek nastane predvsem z delovanjem CYP2C19, k nastanku pa pripomorejo tudi drugi encimi CYP, vključno s CYP1A2, CYP2B6 in CYP3A4.
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis. 
Uporaba 75 mg klopidogrela na dan ni spremenila farmakokinetike S-varfarina (substrata CYP2C9) ali internacionalnega normaliziranega razmerja (INR) pri bolnikih, ki so dolgotrajno prejemali varfarin.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was coadministered with atenolol, nifedipine, or both atenolol and nifedipine. 
Pri sočasni uporabi klopidogrela z atenololom, nifedipinom, ali z obema - atenololom in nifedipinom - niso opazili nobenih klinično pomembnih farmakodinamičnih interakcij.
is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Proces je znan kot aterotromboza in lahko povzroči aterotrombotične dogodke (kot so kap, srčni napad ali smrt).
How to take Clopidogrel Krka d.d. 
Kako jemati zdravilo Clopidogrel Krka d.d.
If you stop taking Clopidogrel Krka d.d. 
Če ste prenehali jemati zdravilo Clopidogrel Krka d.d.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. 
Klopidogrel se najprej presnovi v 2-oksoklopidogrel, ki se presnavlja naprej do aktivnega presnovka, ki je tiolski derivat klopidogrela.
- ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics. 
- Akutni miokardni infarkt z elevacijo ST-spojnice: Zdravljenje začnemo z udarnim 300-mg odmerkom klopidogrela v kombinaciji z ASA in s trombolitiki ali brez njih, nadaljujemo pa 75mg odmerkom enkrat na dan.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents 
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično pomembnih neželenih interakcijah.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy. 
Sočasna heparinska terapija ni pomembno vplivala na relativni delež krvavitev med skupinama bolnikov, ki so se zdravili s klopidogrelom oziroma placebom.
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia 
Bolezni krvi in limfatičnega sistema trombocitopenija, levkopenija, eozinofilija nevtropenija, vključno s hudo nevtropenijo trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Krka d.d. 
Iz varnostnih razlogov naj matere, ki se zdravijo z zdravilom Clopidogrel Krka d.d., ne dojijo.
• Severe hepatic impairment. 
- Huda jetrna okvara.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia. 
ST-spojnice (nestabilna angina ali MI brez Q-zobca) do 24 ur po zadnji epizodi bolečine v prsih ali simptomih, značilnih za ishemijo.
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group .The incidence of major bleeding was similar between groups . 
V študiji CLARITY je v skupini s klopidogrelom in ASA prišlo do splošnega povečanja krvavitev v primerjavi s skupino s placebom in ASA.
Name and address of the manufacturer responsible for batch release 
PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Acquired haemophilia 
Pridobljena hemofilija
Acquired haemophilia has been reported following use of clopidogrel. 
Po uporabi klopidogrela je bila opisana pridobljena hemofilija.
A significantly lower exposure to clopidogrel active metabolite and reduced platelet inhibition has been demonstrated in HIV-infected patients treated with ritonavir- or cobicistat-boosted anti-retroviral therapies (ART). 
Pri bolnikih, okuženih z virusom HIV, ki se zdravijo s protiretrovirusnim zdravljenjem, okrepljenim z ritonavirjem ali kobicistatom, so dokazali pomembno zmanjšano izpostavljenost aktivnemu presnovku klopidogrela in zmanjšano zaviranje trombocitov.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Klopidogrel previdno dajemo bolnikom, ki prejemajo sočasno zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
(4 tablets of 75 mg) once at the start of treatment. 
(štiri 75-mg tablete).
The recommended dose for ASA was 75 to 100 mg/day. 
Priporočeni odmerek ASA je bil od 75 do 100 mg na dan. Bolnike so zdravili do 5 let.
STATEMENT OF ACTIVE SUBSTANCE(S) 
Ime in naslov proizvajalca (proizvajalcev) biološke učinkovine (učinkovin)
If you forget to take a dose of Clopidogrel Krka d.d., but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Če ste pozabili vzeti odmerek in od tega ni minilo več kot 12 ur, ga vzemite takoj, ko se spomnite.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects'). 
Pri manjših urezninah ali poškodbah, npr. pri britju, navadno ni razloga za skrb, če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 "Možni neželeni učinki").
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = 
Pri bolnikih, ki so bili v preizkušanje vključeni samo na podlagi nedavnega MI, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT: -4 %; IZ: -22,5 do 11,7 /p = 0,639/).
While you are taking Clopidogrel Krka d.d. 
Ko jemljete zdravilo Clopidogrel Krka d.d.
contains - The active substance is clopidogrel. 
- Učinkovina je klopidogrel.
SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution. 
Selektivni zaviralci privzema serotonina (SSRI; Selective serotonin re-uptake inhibitors): Selektivni zaviralci privzema serotonina vplivajo na aktivacijo trombocitov in povečajo nevarnost krvavitve, zato je ob sočasnem jemanju selektivnih zaviralcev privzema serotonina in klopidogrela potrebna previdnost.
ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively). 
V skupini s klopidogrelom + ASA je bilo več intrakranialnih krvavitev (1,4 %) kot v skupini s placebom + ASA (0,8 %).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Warnings and precautions''). 
Pri manjših vrezninah ali poškodbah, npr. če se urežete ali brijete, navadno ni razloga za skrb, če pa ste glede krvavitve v kakršnihkoli dvomih, se morate takoj posvetovati s svojim zdravnikom, (glejte poglavje 2 "Opozorila in previdnostni ukrepi").
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions'). 
Nemudoma se posvetujte s svojim zdravnikom, če se pri vas pojavijo: - zvišana telesna temperatura, znaki okužbe ali huda utrujenost, kar so znaki redkega zmanjšanja števila določenih krvnih celic; - znaki jetrnih težav, npr. porumenelost kože in/ali oči (zlatenica), ki so lahko povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 "Opozorila in previdnostni ukrepi"); - otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži kar so lahko znaki alergijske reakcije.
Haematoma 
Encimi
Pharmaceutical Form 
Farmacvtska oblika
EMA Number 
Številka EU
29 May 2013 EMA/313994/2013 
29. maj 2013 EMA/313994/2013
The Agency's recommendations are based on an EU-wide safety review. 
Priporočila agencije temeljijo na varnostnem pregledu na celotnem območju EU.
The review of oral almitrine-containing medicines was initiated in December 2012 at the request of France, under Article 31 of Directive 2001/83/EC. 
Pregled peroralnih zdravil, ki vsebujejo almitrin, je bil sprožen decembra 2012 na zahtevo Francije v skladu s členom 31 Direktive 2001/83/ES.
A review of these data was first conducted by the Pharmacovigilance Risk Assessment Committee (PRAC). 
Pregled teh podatkov je najprej izvedel Odbor za oceno tveganja na področju farmakovigilance (PRAC).
Patients who have any questions should speak to their doctor or pharmacist. 
Bolniki, ki imajo kakršna koli vprašanja, naj se pogovorijo z zdravnikom ali farmacevtom.
Additional results from clinical studies suggested that neuropathy was most common after three months or more of treatment. 
Dodatni rezultati kliničnih študij so pokazali, da je bila nevropatija najpogostejša po zdravljenju, ki je trajalo 3 mesece ali dlje.
PRAC recommendation will be directly implemented following CMDh consensus 
Priporočilo odbora PRAC se bo izvajalo neposredno po sprejetju soglasja v skupini CMDh
The PRAC noted that cases continue to be reported even after additional precautions on the use of the medicines were put in place. 
Odbor PRAC je opazil, da še vedno poročajo o primerih, čeprav so uvedli dodatne previdnostne ukrepe za uporabo teh zdravil.
• Because almitrine has been shown to carry a risk of damage to the nerves in the hands and feet as well as weight loss, and because a number of alternative treatments are now available, it will be withdrawn across the EU. 
• Ker so pokazali, da je pri almitrinu prisotno tveganje za poškodbo živcev v dlaneh in stopalih ter izguba telesne mase, in ker so zdaj na voljo številne druge oblike zdravljenja, bo zdravilo umaknjeno na celotnem območju EU.
• The understanding of COPD and the therapeutic options for its management have changed considerably since the original authorisation of oral almitrine. 
• Razumevanje KOPB in terapevtske možnosti za obravnavo te bolezni so se od prvotne odobritve peroralnega almitrina zelo spremenili.
The Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), a medicines regulatory body representing the EU Member States, has endorsed the recommendation by the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), that permission to market oral medicines containing almitrine should be withdrawn across the European Union (EU). 
Usklajevalna skupina za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMDh), tj. regulativni organ za zdravila, ki predstavlja države članice EU, je potrdila priporočilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) pri Evropski agenciji za zdravila, da je treba dovoljenje za promet s peroralnimi zdravili, ki vsebujejo almitrin, umakniti po celotni Evropski uniji (EU).
The CMDh agreed with the PRAC conclusion that the benefits of these medicines do not outweigh their risks, and adopted a final position that the marketing authorisations should be withdrawn throughout the EU. 
Skupina CMDh se je strinjala s sklepom odbora PRAC, da koristi teh zdravil ne odtehtajo z njimi povezanih tveganj, ter sprejela dokončno stališče, da je treba dovoljenja za promet z zdravili po vsej Evropi umakniti.
The CMDh, a body representing EU Member States, is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU. 
Skupina CMDh je organ, ki zastopa države članice EU, in je odgovorna za zagotovitev enotnih varnostnih standardov za zdravila, ki so v EU odobrena po nacionalnih postopkih.
• Almitrine, a medicine that was authorised several years ago to be taken by mouth to help breathing, is not one of the currently recommended treatments for lung diseases. 
• Almitrin, zdravilo, odobreno pred več leti za pomoč pri dihanju, ki se zaužije skozi usta (peroralno), ni ena od trenutno priporočenih oblik zdravljenja pljučnih bolezni.
These conditions pose a particular problem in patients with lung conditions known as chronic obstructive pulmonary disease (COPD), where the airways and air sacs inside the lungs become damaged or blocked. 
Ti pogoji še zlasti predstavljajo težavo pri bolnikih s pljučno boleznijo, imenovano kronična obstruktivna pljučna bolezen (KOPB), pri kateri postanejo dihalne poti in zračni mešički v pljučih poškodovani ali zaprti.
As almitrine-containing medicines are all authorised nationally, the PRAC recommendations were sent to the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), which adopted a final position. 
Ker so vsa zdravila, ki vsebujejo almitrin, odobrena na nacionalni ravni, so bila priporočila odbora PRAC poslana Usklajevalni skupini za postopek z medsebojnim priznavanjem in decentralizirani postopekzdravila za uporabo v humani medicini (CMDh), ki je sprejela dokončno stališče.